FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States

Jongsook Kim Kemper, Zhen Xiao, Bhaskar Ponugoti, Ji Miao, Sungsoon Fang, Deepthi Kanamaluru, Stephanie Tsang, Shwu Yuan Wu, Cheng Ming Chiang, Timothy D. Veenstra

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

The nuclear bile acid receptor FXR is critical for regulation of lipid and glucose metabolism. Here, we report that FXR is a target of SIRT1, a deacetylase that mediates nutritional and hormonal modulation of hepatic metabolism. Lysine 217 of FXR is the major acetylation site targeted by p300 and SIRT1. Acetylation of FXR increases its stability but inhibits heterodimerization with RXRα, DNA binding, and transactivation activity. Downregulation of hepatic SIRT1 increased FXR acetylation with deleterious metabolic outcomes. Surprisingly, in mouse models of metabolic disease, FXR interaction with SIRT1 and p300 was dramatically altered, FXR acetylation levels were elevated, and overexpression of SIRT1 or resveratrol treatment reduced acetylated FXR levels. Our data demonstrate that FXR acetylation is normally dynamically regulated by p300 and SIRT1 but is constitutively elevated in metabolic disease states. Small molecules that inhibit FXR acetylation by targeting SIRT1 or p300 may be promising therapeutic agents for metabolic disorders.

Original languageEnglish (US)
Pages (from-to)392-404
Number of pages13
JournalCell Metabolism
Volume10
Issue number5
DOIs
StatePublished - Nov 4 2009

Fingerprint

Metabolic Diseases
Acetylation
Liver
Bile Acids and Salts
Lipid Metabolism
Transcriptional Activation
Lysine
Down-Regulation
Glucose
DNA

Keywords

  • HUMDISEASE

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Physiology

Cite this

Kemper, J. K., Xiao, Z., Ponugoti, B., Miao, J., Fang, S., Kanamaluru, D., ... Veenstra, T. D. (2009). FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States. Cell Metabolism, 10(5), 392-404. https://doi.org/10.1016/j.cmet.2009.09.009

FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States. / Kemper, Jongsook Kim; Xiao, Zhen; Ponugoti, Bhaskar; Miao, Ji; Fang, Sungsoon; Kanamaluru, Deepthi; Tsang, Stephanie; Wu, Shwu Yuan; Chiang, Cheng Ming; Veenstra, Timothy D.

In: Cell Metabolism, Vol. 10, No. 5, 04.11.2009, p. 392-404.

Research output: Contribution to journalArticle

Kemper, Jongsook Kim ; Xiao, Zhen ; Ponugoti, Bhaskar ; Miao, Ji ; Fang, Sungsoon ; Kanamaluru, Deepthi ; Tsang, Stephanie ; Wu, Shwu Yuan ; Chiang, Cheng Ming ; Veenstra, Timothy D. / FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States. In: Cell Metabolism. 2009 ; Vol. 10, No. 5. pp. 392-404.
@article{968fea00a8914e9ebd1a0a439e0d12e2,
title = "FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States",
abstract = "The nuclear bile acid receptor FXR is critical for regulation of lipid and glucose metabolism. Here, we report that FXR is a target of SIRT1, a deacetylase that mediates nutritional and hormonal modulation of hepatic metabolism. Lysine 217 of FXR is the major acetylation site targeted by p300 and SIRT1. Acetylation of FXR increases its stability but inhibits heterodimerization with RXRα, DNA binding, and transactivation activity. Downregulation of hepatic SIRT1 increased FXR acetylation with deleterious metabolic outcomes. Surprisingly, in mouse models of metabolic disease, FXR interaction with SIRT1 and p300 was dramatically altered, FXR acetylation levels were elevated, and overexpression of SIRT1 or resveratrol treatment reduced acetylated FXR levels. Our data demonstrate that FXR acetylation is normally dynamically regulated by p300 and SIRT1 but is constitutively elevated in metabolic disease states. Small molecules that inhibit FXR acetylation by targeting SIRT1 or p300 may be promising therapeutic agents for metabolic disorders.",
keywords = "HUMDISEASE",
author = "Kemper, {Jongsook Kim} and Zhen Xiao and Bhaskar Ponugoti and Ji Miao and Sungsoon Fang and Deepthi Kanamaluru and Stephanie Tsang and Wu, {Shwu Yuan} and Chiang, {Cheng Ming} and Veenstra, {Timothy D.}",
year = "2009",
month = "11",
day = "4",
doi = "10.1016/j.cmet.2009.09.009",
language = "English (US)",
volume = "10",
pages = "392--404",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States

AU - Kemper, Jongsook Kim

AU - Xiao, Zhen

AU - Ponugoti, Bhaskar

AU - Miao, Ji

AU - Fang, Sungsoon

AU - Kanamaluru, Deepthi

AU - Tsang, Stephanie

AU - Wu, Shwu Yuan

AU - Chiang, Cheng Ming

AU - Veenstra, Timothy D.

PY - 2009/11/4

Y1 - 2009/11/4

N2 - The nuclear bile acid receptor FXR is critical for regulation of lipid and glucose metabolism. Here, we report that FXR is a target of SIRT1, a deacetylase that mediates nutritional and hormonal modulation of hepatic metabolism. Lysine 217 of FXR is the major acetylation site targeted by p300 and SIRT1. Acetylation of FXR increases its stability but inhibits heterodimerization with RXRα, DNA binding, and transactivation activity. Downregulation of hepatic SIRT1 increased FXR acetylation with deleterious metabolic outcomes. Surprisingly, in mouse models of metabolic disease, FXR interaction with SIRT1 and p300 was dramatically altered, FXR acetylation levels were elevated, and overexpression of SIRT1 or resveratrol treatment reduced acetylated FXR levels. Our data demonstrate that FXR acetylation is normally dynamically regulated by p300 and SIRT1 but is constitutively elevated in metabolic disease states. Small molecules that inhibit FXR acetylation by targeting SIRT1 or p300 may be promising therapeutic agents for metabolic disorders.

AB - The nuclear bile acid receptor FXR is critical for regulation of lipid and glucose metabolism. Here, we report that FXR is a target of SIRT1, a deacetylase that mediates nutritional and hormonal modulation of hepatic metabolism. Lysine 217 of FXR is the major acetylation site targeted by p300 and SIRT1. Acetylation of FXR increases its stability but inhibits heterodimerization with RXRα, DNA binding, and transactivation activity. Downregulation of hepatic SIRT1 increased FXR acetylation with deleterious metabolic outcomes. Surprisingly, in mouse models of metabolic disease, FXR interaction with SIRT1 and p300 was dramatically altered, FXR acetylation levels were elevated, and overexpression of SIRT1 or resveratrol treatment reduced acetylated FXR levels. Our data demonstrate that FXR acetylation is normally dynamically regulated by p300 and SIRT1 but is constitutively elevated in metabolic disease states. Small molecules that inhibit FXR acetylation by targeting SIRT1 or p300 may be promising therapeutic agents for metabolic disorders.

KW - HUMDISEASE

UR - http://www.scopus.com/inward/record.url?scp=70350606061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350606061&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2009.09.009

DO - 10.1016/j.cmet.2009.09.009

M3 - Article

C2 - 19883617

AN - SCOPUS:70350606061

VL - 10

SP - 392

EP - 404

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 5

ER -